ClinicalTrials.gg
Active, not recruitingNCT04964375Updated Nov 6, 2026

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor

A Phase 1 interventional study of ABSK043 oral capsule in Neoplasms, sponsored by Abbisko Therapeutics Co, Ltd. Active, not recruiting at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Abbisko Therapeutics Co, Ltd (part of Abbisko Cayman Limited) · Phase 1, Interventional, and Treatment

Updated Nov 6, 2026Now Active, not recruitingFirst site in China+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1, Open-Label Study of ABSK043 to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Solid Tumor.

Preliminary antitumor activity will also be assessed. Investigate the pharmacodynamics (PD) effects and Investigate the metabolites of oral ABSK043

Read the detailed description

The study will start with a dose escalation part of single-agent ABSK043 administered in repeated 28-day cycles in patients with advanced solid for safety and tolerability. The expansion part of oral ABSK043 at recommended dose of expansion (RDE) will be followed for further evaluating safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.

02

Conditions studied

  • Neoplasms

Browse trials for

03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 102 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Abbisko Therapeutics Co, Ltd is the lead sponsor of 38 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient should understand, sign, and date the written voluntary form prior to screening.
  2. Male or female aged 18 years or older (or other age range required by local regulations or IRB).
  3. For Escalation part: patients must have confirmed solid tumors that have progressed on or intolerance to standard therapy or whom no standard therapy exists or whom refuse to receive standard therapy;

For Expansion Part:

  1. Melanoma cohort: Patients must have histologically confirmed melanoma that have have progressed on or intolerance to standard therapy(including immune-) or whom no standard therapy exists or whom refuses to receive standard therapy
  2. MSI-H/dMMR cohort: Patients must have histologically confirmed solid tumors harboring MSI-H or dMMR that have progressed on or intolerance to standard therapy or whom no standard therapy exists or whom refuses to receive standard therapy.
  3. Patients must have at least one measurable target lesion according to 1.1.
  4. Patients are willing to receive . 4. performance status 0 or 1 5. ≥3 months 6. Adequate organ function and bone marrow function as indicated by the following screening assessments performed within 14 days prior to the first dose of study drug:

    1. (ANC) ≥1.5×109/L
    2. count (PLT) ≥75×109/L without transfusions within 14 days before 1st dose
    3. (Hb) ≥90 g/L
    4. Total (TBIL) ≤1.5×
    5. (AST)/alanine transaminase (ALT), ≤3×ULN (≤5 × ULN in the presence of hepatic ).
    6. Serum creatinine (Cr) of ≤1.5×ULN for the reference laboratory or (Crcl) ≥50 mL/min based either on urine collection or Cockcroft-Gault estimation

Exclusion criteria

Exclusion Criteria:

  1. Known allergy or to any component of the product.
  2. For expansion part MSI-H or dMMR cohort only: previously treated with PD-(L)1 pathway inhibitors (including monoclonal antibody and small molecular agents).
  3. History of disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis, etc.
  4. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan, history of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  5. For expansion part only: Has a known additional that is progressing or required active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or other in situ cancers.
  6. Inability to take oral medication or significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption of oral medication.
  7. Previous anti-cancer therapy, including chemotherapy (chemotherapy with nitrosourea or mitomycin should be 6 weeks prior to initiation of study treatment), radiotherapy, molecular targeted therapy or other investigational drugs received in previous clinical trial ≤4 weeks; endocrine therapy ≤2 weeks or ≤5-half-life (whichever is shorter) prior to initiation of study treatment.
  8. Major surgery within 4 weeks of the first dose of study drug and all surgical wounds must be healed and free of infection or dehiscence.
  9. Vaccination with a live, attenuated vaccine within 4 weeks of the first dose of study treatment and while on trial is prohibited except for administration of inactivate vaccines (e.g., COVID-19 vaccines, inactivated influenza vaccines).
  10. Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy that have not regressed to Grade ≤1 severity ( v5.0) with the exception of alopecia, vitiligo or event(s) that is considered non-clinical meaningful by the Investigator.
  11. History of Grade ≥3 immune-related adverse event(s) occurred in previous treatment.
  12. Treatment with systemic or other systemic medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 2 weeks prior to randomization, or anticipated requirement for systemic immunosuppressive medications during the trial (patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in the study; patients with a history of allergic reaction to IV contrast requiring steroid pre-treatment should have baseline and subsequent tumor assessments performed using MRI; the use of inhaled corticosteroids for , mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension, and low-dose supplemental corticosteroids for adrenocortical insufficiency are allowed.
  13. For expansion part only: last treatment with therapeutic oral or intravenous antibiotics within 2 weeks prior to first dose of study treatment.
  14. Concomitant use of the drugs/remedies that may cause pharmacokinetic drug-drug interactions; Consumption of grapefruit juice, grapefruit hybrids, pomegranates, starfruit, pomelos, Seville oranges or juice or products within 7 days prior to the first dose of study medication (for Escalation Part only).
  15. Active central nervous system (CNS) including cerebral edema, system hormone treatment, disease progression due to intracranial lesions, , and other clinical symptoms related to (if stable disease>8 weeks after treatment and free from glucocorticoids can be enrolled).
  16. Impaired cardiac function or cardiac disease, including any one of the following:

    • class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiacarrhythmia requiring therapy, uncontrolled hypertension or congestive heart failure.
    • Baseline prolongation of the rate- interval based on repeated demonstration of QTcF >480 ms or history of long QT interval corrected (QTc) syndrome (Note: QTc interval corrected by Fridericia's formula). (LVEF) \<50% or below the lower limit of normal(whichever is higher)
  17. Known or active , or active infection or active tuberculosis. Positive tests for hepatitis B virus surface antigen (HBsAg), or antibody to hepatitis B core Ag or hepatitis C RNA in serum. (subjects with history of hepatitis C infection but negative hepatitis C virus polymerase chain reaction (PCR) test and subjects with hepatitis B with positive hepatitis B surface antibody are allowed)
  18. Patients with /uncontrolled ascites or pleural effusion. Patients with indwelling catheters are allowed.
  19. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test within 7 days prior to the start of study drug.
  20. Non-surgically sterilized male or female patients of must agree to use effective methods of during the study and for up to 6 months after the last dose of study drug.
  21. Sexually active males unless they use a condom during intercourse while taking drug and for 5 compound half-lives plus 60 days after stopping study drug and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.
  22. Any other clinically significant comorbidities, such as uncontrolled pulmonary disease, active infection, or any other condition, which in the judgment of the Investigator, could compromise compliance with the protocol, interfere with the interpretation of study results, or predispose the patient to safety risks.
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    ABSK043

    Dose escalation of oral ABSK043 with a starting dose of 200mg once daily will be guided by"BOIN" escalation rules based on safety data until an MTD has been identified or a RDE. For each dose,In the escalation part, sequential cohorts of patients will receive an oral dose of ABSK043 in repeated 28-day cycles. Starting dose level will be 200 mg QD. Cohort 3 on 800mg will be switched to 400mg BID.Then, patients will continuously receive ABSK043 (total daily dose) in repeated 28-day cycles.For the Dose Expansion Phase, patients will each receive orally administered doses of ABSK043 at the RDE in repeated 28-day cycles.

    Drug: ABSK043 oral capsule

Interventions

06

What researchers measure

Primary outcomes

  1. DLT

    dose-limiting toxicity

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. Incidence and Severity of AEs

    Adverse events (AEs), adverse events of special interest (AESIs) and serious adverse events (SAEs)

    Time frame: Through study completion, an average of 6 months

Secondary outcomes

  1. PFS

    Progression-Free Survival

    Time frame: throughout study completion, on average of half year

  2. DCR

    Disease control rate up to 24 weeks

    Time frame: throughout study completion, on average of half year

  3. DOR

    Duration of response

    Time frame: throughout study completion, on average of half year

  4. Cmax

    maximun observed concentration

    Time frame: at the end of Cycle 1 Day15 (each cycle is 28 days)

  5. Tmax

    time to maximum observed concentration

    Time frame: at the end of Cycle 1 Day15 (each cycle is 28 days)

  6. AUC

    area under the concentration-time curve

    Time frame: at the end of Cycle 1 Day15 (each cycle is 28 days)

  7. t1/2

    half-life

    Time frame: at the end of Cycle 1 Day15 (each cycle is 28 days)

  8. Vz/F

    apparent volume of distribution

    Time frame: at the end of Cycle 1 Day15 (each cycle is 28 days)

  9. CL/F

    apparent oral clearance

    Time frame: at the end of Cycle 1 Day15 (each cycle is 28 days)

  10. Css_max

    maximun observed concentration of steady-state

    Time frame: at the end of Cycle 1 Day15 (each cycle is 28 days)

  11. Css_min

    minimum observed concentration of steady-state

    Time frame: at the end of Cycle 1 Day15 (each cycle is 28 days)

  12. AUCss

    area under the concentration-time curve of steady-state

    Time frame: at the end of Cycle 1 Day15 (each cycle is 28 days)

  13. Rac

    accumulation rate

    Time frame: at the end of Cycle 1 Day15 (each cycle is 28 days)

  14. ORR

    Overall response rate

    Time frame: throughout study completion, on average of half year

Other outcomes

  1. surface PD-L1 expression

    Programmed death-ligand 1

    Time frame: Time Frame:at the end of Cycle 1 Day15 (each cycle is 28 days)

  2. metabolites of ABSK043

    any major active metabolites

    Time frame: Time Frame: at the end of Cycle 1 Day15 (each cycle is 28 days)

  3. soluble PD-L1,

    Programmed death-ligand 1

    Time frame: Time Frame:at the end of Cycle 1 Day15 (each cycle is 28 days)

07

Study locations

20 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Jul 2027, 70 months after the start.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's planned 70 months is above that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Oct 2022 → Jul 2027 and completion Mar 2023 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2021
First posted
Jul 16, 2021
StartActual
Aug 31, 2021
Primary completionEst.
Jul 30, 2027was Oct 2022
CompletionEst.
Dec 30, 2027was Mar 2023
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Active, not recruiting
changed Nov 6, 2026
Sites
17 sites added — first site in China
Show 17 added (17 China)
  • Chongqing University Cancer Hospital · Chongqing, China
  • Fujian Cancer hospital · Fuzhou, China
  • First Affiliated Hospital of Gannan Medical University · Ganzhou, China
  • The Second Affiliated Hospital Zhejiang University School of Medicine · Hangzhou, China
  • Harbin Medical University Cancer Hospital · Harbin, China
  • The Second Hospital of Anhui Medical University · Hefei, China
  • Mianyang Central Hospital · Mianyang, China
  • Jiangsu Province Hospital · Nanjing, China
  • Shanghai Chest Hospital · Shanghai, China
  • Shanghai Jiaotong University School of Medicine Ruijin Hospital · Shanghai, China
  • Yuebei People's Hospital · Shaoguan, China
  • Liaoning Cancer Hospital · Shenyang, China
  • Renmin Hospital of Wuhan University · Wuhan, China
  • Union Hospital Tongji Medical College Huazhong University of science and technology · Wuhan, China
  • The First Affiliated Hospital of Xi 'an Jiaotong University · Xi'an, China
  • Xiangyang Central Hospital · Xiangyang, China
  • Yanbian University Hospital(Yanbian Hospital) · Yanbian, China
Nov 6, 2026
Primary completion
Oct 23, 2022→Jul 30, 2027
Nov 6, 2026
Study completion
Mar 23, 2023→Dec 30, 2027
Nov 6, 2026
Enrollment
60 (estimated)→102 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Status unknown→Active, not recruiting
    17 sites added — first site in China
    Show 17 added (17 China)
    • Chongqing University Cancer Hospital · Chongqing, China
    • Fujian Cancer hospital · Fuzhou, China
    • First Affiliated Hospital of Gannan Medical University · Ganzhou, China
    • The Second Affiliated Hospital Zhejiang University School of Medicine · Hangzhou, China
    • Harbin Medical University Cancer Hospital · Harbin, China
    • The Second Hospital of Anhui Medical University · Hefei, China
    • Mianyang Central Hospital · Mianyang, China
    • Jiangsu Province Hospital · Nanjing, China
    • Shanghai Chest Hospital · Shanghai, China
    • Shanghai Jiaotong University School of Medicine Ruijin Hospital · Shanghai, China
    • Yuebei People's Hospital · Shaoguan, China
    • Liaoning Cancer Hospital · Shenyang, China
    • Renmin Hospital of Wuhan University · Wuhan, China
    • Union Hospital Tongji Medical College Huazhong University of science and technology · Wuhan, China
    • The First Affiliated Hospital of Xi 'an Jiaotong University · Xi'an, China
    • Xiangyang Central Hospital · Xiangyang, China
    • Yanbian University Hospital(Yanbian Hospital) · Yanbian, China
    Primary completion Oct 23, 2022→Jul 30, 2027
    Study completion Mar 23, 2023→Dec 30, 2027
    Enrollment 60 (estimated)→102 (actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04964375
Responsible party
Sponsor
First posted
Jul 16, 2021
Start date
Aug 31, 2021
Primary completion
Jul 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Jermaine Coward
principal investigator · Icon Cancer Centre South Brisbane

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PD-L1 Inhibitor ABSK043

Start the discussion